Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

Federal attacks on universities and research funding could destroy centuries of progress in innovation, threatening ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.

People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a ...

It’s common to feel nervous (and maybe even spaced out) when your doctor demonstrates how to inject yourself with ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

A federal judge's ruling essentially blocks compound pharmacies from selling less-expensive, unapproved versions of Ozempic ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

WeightWatchers will file for bankruptcy in the coming weeks after finally negotiating a deal on its $1.6 billion of debt.

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...